Published in Cell on May 29, 1998
HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature (2012) 3.63
Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo. J Virol (2000) 3.48
Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. EMBO J (2007) 2.37
Tat-associated kinase, TAK, activity is regulated by distinct mechanisms in peripheral blood lymphocytes and promonocytic cell lines. J Virol (1998) 1.93
HIV-1 Nef increases T cell activation in a stimulus-dependent manner. Proc Natl Acad Sci U S A (1999) 1.92
Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A (2000) 1.83
A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children. J Clin Invest (2000) 1.81
Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput Biol (2009) 1.78
Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics. J Virol (2007) 1.77
Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci U S A (2008) 1.72
Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev (2013) 1.68
HIV-1 Tat protein mimicry of chemokines. Proc Natl Acad Sci U S A (1998) 1.67
Availability of activated CD4+ T cells dictates the level of viremia in naturally SIV-infected sooty mangabeys. J Clin Invest (2008) 1.57
Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. J Virol (1999) 1.54
Modeling HIV persistence, the latent reservoir, and viral blips. J Theor Biol (2009) 1.49
Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: low virus production in vivo. J Virol (2000) 1.46
HIV-1 Nef binds the DOCK2-ELMO1 complex to activate rac and inhibit lymphocyte chemotaxis. PLoS Biol (2004) 1.44
An in vitro rapid-turnover assay for human immunodeficiency virus type 1 replication selects for cell-to-cell spread of virus. J Virol (2000) 1.44
In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies. Proc Natl Acad Sci U S A (2001) 1.40
Cell-associated HIV RNA: a dynamic biomarker of viral persistence. Retrovirology (2013) 1.37
HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission. AIDS (2008) 1.36
Viral and latent reservoir persistence in HIV-1-infected patients on therapy. PLoS Comput Biol (2006) 1.35
Induction of cell death in human immunodeficiency virus-infected macrophages and resting memory CD4 T cells by TRAIL/Apo2l. J Virol (2001) 1.34
Comparison of NucliSens and Roche Monitor assays for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (1999) 1.32
CD4-Negative cells bind human immunodeficiency virus type 1 and efficiently transfer virus to T cells. J Virol (2000) 1.31
Modeling the within-host dynamics of HIV infection. BMC Biol (2013) 1.29
Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest (2002) 1.26
Tetraspanins in viral infections: a fundamental role in viral biology? J Virol (2005) 1.16
Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture. Antimicrob Agents Chemother (2009) 1.15
HIV-1 dynamics revisited: biphasic decay by cytotoxic T lymphocyte killing? Proc Biol Sci (2000) 1.15
The role of antigenic stimulation and cytotoxic T cell activity in regulating the long-term immunopathogenesis of HIV: mechanisms and clinical implications. Proc Biol Sci (2001) 1.14
Antigen-driven CD4+ T cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1999) 1.08
DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev (2004) 1.06
Brownian adhesive dynamics (BRAD) for simulating the receptor-mediated binding of viruses. Biophys J (2004) 0.97
Multiple effects of an anti-human immunodeficiency virus nucleocapsid inhibitor on virus morphology and replication. J Virol (1999) 0.94
Decreases in plasma TNF-alpha level and IFN-gamma mRNA level in peripheral blood mononuclear cells (PBMC) and an increase in IL-2 mRNA level in PBMC are associated with effective highly active antiretroviral therapy in HIV-infected patients. Clin Exp Immunol (2003) 0.93
A simple relationship between viral load and survival time in HIV-1 infection. Proc Natl Acad Sci U S A (1999) 0.92
Reconsidering targeted toxins to eliminate HIV infection: you gotta have HAART. Proc Natl Acad Sci U S A (1998) 0.92
HIV-1 Nef enhances dendritic cell-mediated viral transmission to CD4+ T cells and promotes T-cell activation. PLoS One (2012) 0.85
Role of glycosphingolipids in dendritic cell-mediated HIV-1 trans-infection. Adv Exp Med Biol (2013) 0.84
Influence of follicular dendritic cells on HIV dynamics. Philos Trans R Soc Lond B Biol Sci (2000) 0.84
Contribution of follicular dendritic cells to persistent HIV viremia. J Virol (2013) 0.83
Transfer of human CD4(+) T lymphocytes producing beta interferon in Hu-PBL-SCID mice controls human immunodeficiency virus infection. J Virol (1999) 0.83
Rapid human immunodeficiency virus decay in highly active antiretroviral therapy (HAART)-experienced children after starting mega-HAART. J Virol (2004) 0.82
Expression of MHC class II in T cells is associated with increased HIV-1 expression. Clin Exp Immunol (2000) 0.77
Reservoirs for HIV-1. Curr Infect Dis Rep (1999) 0.77
Variation of human immunodeficiency virus type-1 reverse transcriptase within the simian immunodeficiency virus genome of RT-SHIV. PLoS One (2014) 0.77
Infection with HIV-1. BMJ (1998) 0.76
Nigella sativa concoction induced sustained seroreversion in HIV patient. Afr J Tradit Complement Altern Med (2013) 0.76
Microdevices for examining immunological responses of single cells to HIV. Biosci Rep (2014) 0.75
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (1997) 15.49
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68
In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med (1995) 6.26
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A (2009) 4.58
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol (2000) 4.46
A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature (1988) 4.15
HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. JAMA (2001) 3.41
Endocytosis of endogenously synthesized HIV-1 envelope protein. Mechanism and role in processing for association with class II MHC. J Immunol (1995) 2.62
Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein. Nature (1985) 2.51
Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection. J Infect Dis (2000) 2.25
Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1. J Virol (2000) 1.95
The human immunodeficiency virus type 1 gag gene encodes an internal ribosome entry site. J Virol (2001) 1.87
A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children. J Clin Invest (2000) 1.81
Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine. Science (1990) 1.78
Role of interaction of CD2 molecules with lymphocyte function-associated antigen 3 in T-cell recognition of nominal antigen. Proc Natl Acad Sci U S A (1990) 1.44
Characterization of a conserved T cell epitope in HIV-1 gp41 recognized by vaccine-induced human cytolytic T cells. J Immunol (1991) 1.38
Direct evidence for the existence of nominal antigen binding sites on T cell surface Ti alpha-beta heterodimers of MHC-restricted T cell clones. Cell (1986) 1.32
A soluble, single-chain T-cell receptor fragment endowed with antigen-combining properties. Proc Natl Acad Sci U S A (1991) 1.28
Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. J Infect Dis (1995) 1.26
A novel method for detection and ex vivo expansion of HIV type 1-specific cytolytic T lymphocytes. AIDS Res Hum Retroviruses (1994) 1.25
Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J Exp Med (1997) 1.25
Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. J Infect Dis (1999) 1.21
Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution. J Infect Dis (2001) 1.19
The interaction of nominal antigen with T cell antigen receptors. I. Specific binding of multivalent nominal antigen to cytolytic T cell clones. J Immunol (1985) 1.17
Autologous strain-specific cytolytic T lymphocyte responses directed against human immunodeficiency virus type 1 Env. AIDS Res Hum Retroviruses (1998) 1.17
Anchor sequence-dependent endogenous processing of human immunodeficiency virus 1 envelope glycoprotein gp160 for CD4+ T cell recognition. J Exp Med (1990) 1.17
A human nuclear shuttling protein that interacts with human immunodeficiency virus type 1 matrix is packaged into virions. J Virol (2000) 1.16
Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T cells. J Immunol (1995) 1.12
Differential susceptibility of naive and memory CD4+ T cells to the cytopathic effects of infection with human immunodeficiency virus type 1 strain LAI. J Virol (1997) 1.11
The human NTT gene: identification of a novel 17-kb noncoding nuclear RNA expressed in activated CD4+ T cells. Genomics (1997) 1.06
Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines. J Exp Med (1992) 1.05
Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework. Biophys J (2010) 1.00
Production of transmembrane and secreted forms of tumor necrosis factor (TNF)-alpha by HIV-1-specific CD4+ cytolytic T lymphocyte clones. Evidence for a TNF-alpha-independent cytolytic mechanism. J Immunol (1992) 0.96
Major histocompatibility complex independent T cell receptor-antigen interaction: functional analysis using fluorescein derivatives. J Exp Med (1991) 0.95
Processing of HIV-1 envelope glycoprotein for class I-restricted recognition: dependence on TAP1/2 and mechanisms for cytosolic localization. J Immunol (1999) 0.95
An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes. J Immunol (1993) 0.94
HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor. Lancet (1998) 0.90
Suppression of antibody-sensitized tumor cells by macrophages: insufficient supply or activation of macrophages within large tumors. J Immunol (1979) 0.89
HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization, and quantitation. AIDS Res Hum Retroviruses (1997) 0.88
Latency and viral persistence in HIV-1 infection. J Clin Invest (2000) 0.88
HIV-1 envelope protein is expressed on the surface of infected cells before its processing and presentation to class II-restricted T lymphocytes. J Immunol (1993) 0.88
The enhanced immune response to the HIV gp160/LAMP chimeric gene product targeted to the lysosome membrane protein trafficking pathway. J Biol Chem (1997) 0.86
Acidic residues in the DR beta chain third hypervariable region are required for stimulation of a DR(alpha, beta 1*0402)-restricted T-cell clone. Hum Immunol (1994) 0.86
Class I-restricted presentation of an HIV-1 gp41 epitope containing an N-linked glycosylation site. Implications for the mechanism of processing of viral envelope proteins. J Immunol (1996) 0.85
Studies of the mechanism of cytolysis by HIV-1-specific CD4+ human CTL clones induced by candidate AIDS vaccines. J Immunol (1994) 0.85
Latent reservoirs for HIV-1. Curr Opin Infect Dis (1999) 0.84
Studies on the mechanism of lymphocyte-mediated cytolysis. X. Enucleated cells as targets for cytotoxic attack. J Immunol (1978) 0.84
Genetic variability in HIV-1 gp120 affects interactions with HLA molecules and T cell receptor. J Immunol (1990) 0.84
Antigen valence determines the binding of nominal antigen to cytolytic T cell clones. J Exp Med (1985) 0.83
Preventing AIDS but not HIV-1 infection with a DNA vaccine. Science (2000) 0.82
The diversity of T cell receptors specific for self MHC gene products. J Immunol (1983) 0.82
Cutting edge: induction of enhanced CTL-dependent protective immunity in vivo by N-end rule targeting of a model tumor antigen. J Immunol (1999) 0.81
Cytokines from vaccine-induced HIV-1 specific cytotoxic T lymphocytes: effects on viral replication. AIDS Res Hum Retroviruses (1993) 0.81
H-2 restriction: independent recognition of H-2 and foreign antigen by a single receptor. Proc Natl Acad Sci U S A (1980) 0.80
Human immunodeficiency virus glycoprotein-specific CD4+ cytotoxic T lymphocytes are involved in two types of cytotoxicity: antigen-specific and cell-cell fusion-related cell lysis. AIDS Res Hum Retroviruses (1997) 0.80
Human CD4+ cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine. J Infect Dis (1993) 0.80
Mapping of specific and promiscuous HLA-DR-restricted T-cell epitopes on the Plasmodium falciparum 27-kilodalton sexual stage-specific antigen. Infect Immun (1998) 0.80
Characterization of a polyclonal cytolytic T lymphocyte response to human immunodeficiency virus in persons without clinical progression. J Infect Dis (1997) 0.80
Interleukin 2 treatment for HIV infection. JAMA (2000) 0.78
Epitope specificity of MHC restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine. AIDS Res Hum Retroviruses (1994) 0.78
Establishment of latent HIV-1 infection of resting CD4(+) T lymphocytes does not require inactivation of Vpr. Virology (2000) 0.77
Cellular immune responses to HIV-1. AIDS (1998) 0.77
Taking aim at HIV replication. Nat Med (2000) 0.77
The ins and outs of HIV endocytosis. Trends Cell Biol (1997) 0.76
MHC class II genotype and the control of viremia in HIV-1-infected individuals on highly active antiretroviral therapy. J Clin Invest (2001) 0.76
Cellular immune responses to HIV-1 in progressive and non-progressive infections. AIDS (1996) 0.76
Retracted A lymphokine that activates the cytolytic program of both cytotoxic T lymphocyte and natural killer clones. J Exp Med (1986) 0.75
A reservoir for HIV in patients on combination antiretroviral therapy. Hopkins HIV Rep (1998) 0.75
Chloramphenicol metabolism in isolated rat hepatocytes. Biochem Pharmacol (1978) 0.75
Structured therapeutic interruptions: a review. Hopkins HIV Rep (2001) 0.75
An algorithm for evaluating human cytotoxic T lymphocyte responses to candidate AIDS vaccines. AIDS Res Hum Retroviruses (1999) 0.75
Human T lymphocyte activation. Adv Exp Med Biol (1987) 0.75